Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

A new statistical methodology overcame the defects of the Bland & Altman method.

Taffé P, Halfon P, Halfon M.

J Clin Epidemiol. 2020 Apr 1. pii: S0895-4356(19)30293-8. doi: 10.1016/j.jclinepi.2020.03.018. [Epub ahead of print]

PMID:
32247027
2.

Paradoxical association between blood modular interferon signatures and quality of life in patients with systemic lupus erythematosus.

Seguier J, Jouve E, Bobot M, Whalen E, Dussol B, Gentile S, Burtey S, Halfon P, Retornaz F, Chaussabel D, Chiche L, Jourde-Chiche N.

Rheumatology (Oxford). 2019 Nov 27. pii: kez541. doi: 10.1093/rheumatology/kez541. [Epub ahead of print]

PMID:
31776548
3.

Full-Term Human Placental Macrophages Eliminate Coxiella burnetii Through an IFN-γ Autocrine Loop.

Mezouar S, Benammar I, Boumaza A, Diallo AB, Chartier C, Buffat C, Boudjarane J, Halfon P, Katsogiannou M, Mege JL.

Front Microbiol. 2019 Oct 29;10:2434. doi: 10.3389/fmicb.2019.02434. eCollection 2019.

4.

Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.

Garioud A, Heng R, Amiot X, Rémy AJ, Ollivier-Hourmand I, Mokhtari C, Medmoun M, Renou C, Zougmoré H, Pulwermacher P, Lucidarme D, Rosa-Hézode I, Causse X, Arotcarena R, Zanditenas D, Halfon P, Pariente A, Cadranel JF; Association Nationale des Hépato-gastroentérologues des Hôpitaux Généraux (ANGH), France.

Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1270-1274. doi: 10.1097/MEG.0000000000001450.

PMID:
31219848
5.

GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.

Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.

Invest New Drugs. 2019 Dec;37(6):1135-1145. doi: 10.1007/s10637-019-00741-3. Epub 2019 Feb 19.

PMID:
30778887
6.

[Hepatitis C virus infection, 1989-2019: From discovery to eradication].

Cacoub P, Halfon P.

Rev Med Interne. 2019 Sep;40(9):567-569. doi: 10.1016/j.revmed.2018.12.007. Epub 2019 Jan 9. French. No abstract available.

PMID:
30638702
7.

Quantification of HPV16 E6/E7 mRNA Spliced Isoforms Viral Load as a Novel Diagnostic Tool for Improving Cervical Cancer Screening.

Camus C, Vitale S, Loubatier C, Pénaranda G, Khiri H, Plauzolles A, Carcopino X, Halfon P, Giordanengo V.

J Clin Med. 2018 Dec 8;7(12). pii: E530. doi: 10.3390/jcm7120530.

8.

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.

Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC.

J Mol Diagn. 2018 Jul;20(4):483-494. doi: 10.1016/j.jmoldx.2018.03.006. Epub 2018 Apr 26.

9.

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

J Hepatol. 2018 Mar;68(3):595-597. doi: 10.1016/j.jhep.2017.09.019. Epub 2017 Oct 4. No abstract available.

PMID:
28987520
10.

Baseline and post-treatment hepatitis C NS5A resistance in relapsed patients from a multicentric real-life cohort.

Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P, Zoulim F, Alric L, Métivier S, Leroy V, Ouzan D, de Lédinghen V, Mohamed S, Pénaranda G, Khiri H, Thélu MA, Plauzolles A, Chiche L, Bourlière M, Abravanel F.

Antivir Ther. 2018;23(4):307-314. doi: 10.3851/IMP3184.

PMID:
28730994
11.

Performance of Real-Time Polymerase Chain Reaction Assays for the Detection of 20 Gastrointestinal Parasites in Clinical Samples from Senegal.

Sow D, Parola P, Sylla K, Ndiaye M, Delaunay P, Halfon P, Camiade S, Dieng T, Tine RCK, Faye B, Ndiaye JL, Dieng Y, Gaye O, Raoult D, Bittar F.

Am J Trop Med Hyg. 2017 Jul;97(1):173-182. doi: 10.4269/ajtmh.16-0781.

12.

HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?

Philibert P, Chiche L, Caillères S, Allemand J, Rebaudet S, Delord M, Stavris C, Retornaz F, Khiri H, Halfon P.

AIDS. 2017 Sep 24;31(15):2167-2169. doi: 10.1097/QAD.0000000000001588.

PMID:
28692546
13.

Obituary: HIV/AIDS researcher Mark Wainberg passed away.

Halfon P, Soriano V.

AIDS Rev. 2017 Apr - Jun;19(2):115. No abstract available.

PMID:
28664943
14.

Adverse events related to hospital care: a retrospective medical records review in a Swiss hospital.

Halfon P, Staines A, Burnand B.

Int J Qual Health Care. 2017 Aug 1;29(4):527-533. doi: 10.1093/intqhc/mzx061.

PMID:
28586414
15.

Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.

Kostine M, Chiche L, Lazaro E, Halfon P, Charpin C, Arniaud D, Retornaz F, Blanco P, Jourde-Chiche N, Richez C, Stavris C.

Rev Med Interne. 2017 Aug;38(8):513-525. doi: 10.1016/j.revmed.2017.01.004. Epub 2017 Feb 15. Review.

PMID:
28214182
16.

Point-of-Care Versus Central Laboratory Measurements of Hemoglobin, Hematocrit, Glucose, Bicarbonate and Electrolytes: A Prospective Observational Study in Critically Ill Patients.

Allardet-Servent J, Lebsir M, Dubroca C, Fabrigoule M, Jordana S, Signouret T, Castanier M, Thomas G, Soundaravelou R, Lepidi A, Delapierre L, Penaranda G, Halfon P, Seghboyan JM.

PLoS One. 2017 Jan 10;12(1):e0169593. doi: 10.1371/journal.pone.0169593. eCollection 2017.

17.

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).

Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group.

Antivir Ther. 2017;22(6):461-469. doi: 10.3851/IMP3074. Epub 2016 Sep 1.

PMID:
27583701
18.

Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model.

Lagaye S, Brun S, Gaston J, Shen H, Stranska R, Camus C, Dubray C, Rousseau G, Massault PP, Courcambeck J, Bassisi F, Halfon P, Pol S.

World J Hepatol. 2016 Jul 28;8(21):902-14. doi: 10.4254/wjh.v8.i21.902.

19.

Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis.

Jarrot PA, Chiche L, Hervier B, Daniel L, Vuiblet V, Bardin N, Bertin D, Terrier B, Amoura Z, Andrés E, Rondeau E, Hamidou M, Pennaforte JL, Halfon P, Daugas E, Dussol B, Puéchal X, Kaplanski G, Jourde-Chiche N.

Medicine (Baltimore). 2016 May;95(22):e3748. doi: 10.1097/MD.0000000000003748.

20.

Resurrection of response-guided therapy for sofosbuvir combination therapies.

Dahari H, Halfon P, Cotler SJ.

J Hepatol. 2016 Sep;65(3):462-4. doi: 10.1016/j.jhep.2016.05.028. Epub 2016 May 27. No abstract available.

21.

Hepatitis C genotype 4R resistance-associated polymorphisms: The achilles heel of the nonstructural 5A inhibitors?

Halfon P, Mohamed S, Penaranda G, Khiri H, Chiche L, Nicolas C, Abergel A.

Hepatology. 2016 Aug;64(2):697-8. doi: 10.1002/hep.28611. Epub 2016 Jun 1. No abstract available.

PMID:
27118238
22.

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.

Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group.

HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11.

23.

Genotyping and follow-up of HR-HPV types detected by self-sampling in women from low socioeconomic groups not participating in regular cervical cancer screening in France.

Tamalet C, Halfon P, Retraite LL, Grob A, Leandri FX, Heid P, Sancho-Garnier H, Piana L.

J Clin Virol. 2016 May;78:102-7. doi: 10.1016/j.jcv.2016.02.027. Epub 2016 Mar 17.

PMID:
27015435
24.

Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.

Mohamed S, Bourliere M, Benali S, Oules V, Castellani P, Khiri H, Camus C, Penaranda G, Chiche L, Gonzalez D, Sayada C, Olive D, Halfon P.

J Clin Virol. 2016 May;78:36-43. doi: 10.1016/j.jcv.2016.02.022. Epub 2016 Feb 26.

PMID:
26971166
25.

Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV-HCV genotype 1 coinfection.

Lison H, Garioud A, Halfon P, Jambon S, Cordier F, Verbrigghe C, Landgraf N, Pitre C, Nguyen-Khac E, Cadranel JF.

Eur J Gastroenterol Hepatol. 2016 Apr;28(4):486-7. doi: 10.1097/MEG.0000000000000508. No abstract available.

PMID:
26934415
26.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.

27.

Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.

Bourlière M, Adhoute X, Ansaldi C, Oules V, Benali S, Portal I, Castellani P, Halfon P.

Expert Rev Gastroenterol Hepatol. 2015;9(12):1483-94. doi: 10.1586/17474124.2015.1111757. Epub 2015 Nov 23. Review.

PMID:
26595560
28.

Faecal microbiota transplantation as salvage therapy for fulminant Clostridium difficile infections.

Million M, Hocquart M, Seghboyan JM, Griffiths K, Halfon P, Lagier JC, Brouqui P, Raoult D.

Int J Antimicrob Agents. 2015 Aug;46(2):227-8. doi: 10.1016/j.ijantimicag.2015.05.002. Epub 2015 Jun 3. No abstract available.

PMID:
26092095
29.

[Diagnosis and clinical management of cervical HPV infections].

Carcopino X, Camus C, Halfon P.

Presse Med. 2015 Jul-Aug;44(7-8):716-26. doi: 10.1016/j.lpm.2015.02.020. Epub 2015 Jun 9. Review. French. No abstract available.

PMID:
26067573
30.

Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study.

Kessler HH, Cobb BR, Wedemeyer H, Maasoumy B, Michel-Treil V, Ceccherini-Nelli L, Bremer B, Hübner M, Helander A, Khiri H, Heilek G, Simon CO, Luk K, Aslam S, Halfon P.

J Clin Virol. 2015 Jun;67:67-72. doi: 10.1016/j.jcv.2015.03.023. Epub 2015 Mar 31.

PMID:
25959162
31.

Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.

Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramière C, Scholtes C, Haïm-Boukobza S, Roque-Afonso AM, Besse B, André-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P.

J Clin Microbiol. 2015 Jul;53(7):2195-202. doi: 10.1128/JCM.03633-14. Epub 2015 Apr 29.

32.
33.

Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice.

Halfon P, Penaranda G, Mohamed S, Camus C, Khiri H.

Eur J Gastroenterol Hepatol. 2015 May;27(5):557-60. doi: 10.1097/MEG.0000000000000326.

PMID:
25822864
34.

IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections.

Sertorio M, Hou X, Carmo RF, Dessein H, Cabantous S, Abdelwahed M, Romano A, Albuquerque F, Vasconcelos L, Carmo T, Li J, Varoquaux A, Arnaud V, Oliveira P, Hamdoun A, He H, Adbelmaboud S, Mergani A, Zhou J, Monis A, Pereira LB, Halfon P, Bourlière M, Parana R, Dos Reis M, Gonnelli D, Moura P, Elwali NE, Argiro L, Li Y, Dessein A.

Hepatology. 2015 Apr;61(4):1321-31. doi: 10.1002/hep.27629. Epub 2015 Mar 10.

PMID:
25476703
35.

A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success.

Halfon P, Pénaranda G, Ouzan D.

J Hepatol. 2015 Jan;62(1):238. doi: 10.1016/j.jhep.2014.08.055. Epub 2014 Oct 13. No abstract available.

36.

Impact of common risk factors of fibrosis progression in chronic hepatitis C.

Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F.

Gut. 2015 Oct;64(10):1605-15. doi: 10.1136/gutjnl-2014-306997. Epub 2014 Sep 11.

PMID:
25214320
37.

Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic.

Lafeuillade A, Wainberg M, Gougeon ML, Loes SK, Halfon P, Tissot-Dupont H.

AIDS Res Ther. 2014 Aug 21;11:28. doi: 10.1186/1742-6405-11-28. eCollection 2014.

38.

Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohort.

Halfon P, Ouzan D, Asselah T, Renou C, Allègre T, Delasalle P, Lafeuillade A, Cadranel JF, Haddad N, Khiri H, Pénaranda G, Bourlière M; Iliade Investigators.

Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):720-6. doi: 10.1016/j.clinre.2014.06.004. Epub 2014 Jul 14.

PMID:
25034356
39.

[Cytological and virological medium performance and stability assessment using the Cobas 4800 HPV test (Roche Diagnostics) used in France].

Khiri H, Camus C, Portugal M, Pénaranda G, Boyer S, Halfon P.

Ann Biol Clin (Paris). 2014 Mar-Apr;72(2):213-23. doi: 10.1684/abc.2014.0932. French.

40.

Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.

Mohamed S, Penaranda G, Gonzalez D, Camus C, Khiri H, Boulmé R, Sayada C, Philibert P, Olive D, Halfon P.

AIDS. 2014 Jun 1;28(9):1315-24. doi: 10.1097/QAD.0000000000000267.

PMID:
24698843
41.

[Treatment of hepatitis C with new direct antiviral drugs: towards a disease cure].

Halfon P, Cacoub P.

Rev Med Interne. 2014 Apr;35(4):219-21. doi: 10.1016/j.revmed.2013.12.017. Epub 2014 Feb 19. French. No abstract available.

PMID:
24559772
43.

Taenia in the gastrointestinal tract after "figatellu" ingestion.

Halfon P, Pénaranda G, Belgodére O.

Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):243-4. doi: 10.1016/j.clinre.2013.10.006. Epub 2013 Dec 30. No abstract available.

PMID:
24388341
44.

HCV direct-acting antiviral agents: the best interferon-free combinations.

Schinazi R, Halfon P, Marcellin P, Asselah T.

Liver Int. 2014 Feb;34 Suppl 1:69-78. doi: 10.1111/liv.12423. Review.

PMID:
24373081
45.

High Prevalence of Asymptomatic Sexually Transmitted Infections among Men Who Have Sex with Men.

Philibert P, Khiri H, Pénaranda G, Camus C, Drogoul MP, Halfon P.

J Clin Med. 2014 Dec 12;3(4):1386-91. doi: 10.3390/jcm3041386.

46.

Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.

Mohamed S, Ravet S, Camus C, Khiri H, Olive D, Halfon P.

J Med Virol. 2014 Mar;86(3):394-403. doi: 10.1002/jmv.23853. Epub 2013 Nov 19.

PMID:
24248806
47.

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.

Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, Aslam S, Manns MP, Cornberg M, Wedemeyer H.

Aliment Pharmacol Ther. 2014 Jan;39(1):85-92. doi: 10.1111/apt.12544. Epub 2013 Nov 10.

48.

Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.

Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P.

J Clin Virol. 2013 Dec;58(4):713-7. doi: 10.1016/j.jcv.2013.09.020. Epub 2013 Sep 29.

PMID:
24183313
49.

Disease identification based on ambulatory drugs dispensation and in-hospital ICD-10 diagnoses: a comparison.

Halfon P, Eggli Y, Decollogny A, Seker E.

BMC Health Serv Res. 2013 Oct 31;13:453. doi: 10.1186/1472-6963-13-453.

50.

Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays.

Halfon P, Sandri MT, Raimondo A, Ravet S, Khiri H, Sideri M, Penaranda G, Camus C, Mateos Lindemann ML.

BMC Infect Dis. 2013 Oct 24;13:499. doi: 10.1186/1471-2334-13-499.

Supplemental Content

Loading ...
Support Center